Peter Marks says Sarepta gene therapy pause ‘makes sense’news2025-07-18T19:05:54+00:00July 18th, 2025|Endpoints News|
Sarepta lays off 500 people, adds black box warning to DMD therapynews2025-07-16T21:02:25+00:00July 16th, 2025|Endpoints News|
FDA rejects Ultragenyx’s Sanfilippo gene therapy over manufacturing issuesnews2025-07-14T11:38:31+00:00July 14th, 2025|Endpoints News|
AstraZeneca’s Alexion inks AAV capsid deal with JCR Pharmanews2025-07-09T11:07:05+00:00July 9th, 2025|Endpoints News|
‘CRISPR Cures’ center launches to make custom gene editing therapiesnews2025-07-08T19:59:53+00:00July 8th, 2025|Endpoints News|
Shell company Concentra has found its rhythm, with Cargo Therapeutics as its latest buyout targetnews2025-07-08T11:25:01+00:00July 8th, 2025|Endpoints News|
SCG Cell Therapy gets China thumbs-up for study of potentially curative HBV treatmentnews2025-07-08T11:17:10+00:00July 8th, 2025|Endpoints News|
Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trialnews2025-07-01T14:48:52+00:00July 1st, 2025|Endpoints News|
CEOs push EU for cell, gene therapy incentives in Biotech Actnews2025-06-27T16:22:05+00:00June 27th, 2025|Endpoints News|
Bayer’s BlueRock prioritizes neurology, eye programs, lays off about 50 staffersnews2025-06-25T14:14:15+00:00June 25th, 2025|Endpoints News|
